Search the Newsreel

EquipmentShare.com Reports Q2 2026 Results: Full Earnings Call Transcript

EquipmentShare.com reported strong Q2 2026 results, with a 39% increase in rental segment revenue and 55% margins at mature rental locations. The company authorized a $500 million share repurchase program and provided a full-year rental segment revenue growth outlook of approximately 33%, despite a …

EquipmentShare.com Inc. (EQPT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against EquipmentShare.com Inc. (EQPT), inviting shareholders who suffered losses between January 23, 2026, and June 23, 2026, to become lead plaintiffs. The lawsuit alleges that EquipmentShare.com Inc. failed to disclose …

Bronstein, Gewirtz & Grossman LLC Urges EquipmentShare.com Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against EquipmentShare.com Inc. (NASDAQ: EQPT) alleging federal securities law violations. The lawsuit claims that EquipmentShare made materially false and misleading statements regarding undisclosed related-party transactions and the company's financial condition. Investors who purchased …

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 21, 2026 in Equipmentshare.com Inc. Lawsuit - EQPT

The Gross Law Firm is notifying shareholders of Equipmentshare.com Inc. (NASDAQ: EQPT) about a lead plaintiff deadline of September 21, 2026, in a class action lawsuit. The lawsuit alleges that the company made materially false and misleading statements regarding undisclosed related-party transactions and financial …

EquipmentShare.com (EQPT) Stock Rallies On Profit Reset With EPS Questions

Taysha Gene Therapies (TSHA) Stock Retreats As Cash Burn Deepens

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have reported a beneficial ownership of 16,244,339 shares, or 5.1%, of Taysha Gene Therapies, Inc. common stock as of June 30, 2026. This disclosure was made in an Amendment No. 2 to Schedule 13G …

SueWallSt Reminds EquipmentShare.com Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 21, 2026 - EQPT

SueWallSt is reminding investors of EquipmentShare.com Inc. (NASDAQ: EQPT) about a pending class action lawsuit with a lead plaintiff deadline of September 21, 2026. The lawsuit alleges that EquipmentShare made materially false or misleading statements regarding undisclosed related-party transactions in its IPO filings and …

EquipmentShare.com Q2 Earnings Call Highlights

Key Points Interested in EquipmentShare.com Inc? Here are five stocks we like better. Strong second-quarter growth: Revenue rose 26% year over year to $1.4 billion, rental revenue increased 39% to $908 million, and adjusted core EBITDA grew 34% to $531 million. Management cited strong …

EquipmentShare (EQPT) grows Q2 revenue post-IPO but carries heavy debt load

Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return

Taysha Gene Therapies (TSHA) has seen a significant 232% return over three years, yet its current valuation, particularly its Price-to-Book ratio of 9.8x against an industry average of 2.5x, suggests it trades at a premium. The company's valuation appears to already price in expectations …

EquipmentShare.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against EquipmentShare.com Inc. - EQPT

ClaimsFiler is reminding investors of EquipmentShare.com Inc. (EQPT) who have suffered losses exceeding $100,000 that the lead plaintiff deadline for a securities class action lawsuit is September 21, 2026. The lawsuit alleges that EquipmentShare and its executives failed to disclose material information regarding undisclosed …

Kaplan Fox Class Action Reminder: EquipmentShare.Com Inc (NASDAQ: EQPT) Lead Plaintiff Deadline is September 21, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against EquipmentShare.Com Inc (NASDAQ: EQPT) on behalf of investors who purchased shares related to its January 23, 2026 IPO or during the Class Period of January 23, 2026, to June 23, 2026. The …

EquipmentShare Reports Second Quarter 2026 Results with 39% Rental Segment Revenue Growth and Strong Adjusted Core EBITDA Increase

EquipmentShare.com Stock Drop – If You Incurred Significant Losses Investing in EQPT Contact Robbins LLP for Information About Leading the Securities Class Action

Robbins LLP has filed a securities class action lawsuit against EquipmentShare.com, Inc. (NASDAQ: EQPT) on behalf of investors who incurred losses from the company's January 2026 IPO and subsequent stock purchases between January 23 and June 23, 2026. The lawsuit alleges that EquipmentShare made …

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

EQUIPMENTSHARE.COM, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 21, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Bernstein Liebhard LLP reminds investors of EquipmentShare.com, Inc. (NASDAQ: EQPT) about the September 21, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit alleges that EquipmentShare made materially false and misleading statements regarding its business, leading to inflated stock prices and …

Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside

Taysha Gene Therapies, Inc.'s stock has seen its average 12-month price target increased to $13.33, up from $13.25, according to 12 analysts. This new target implies a potential 100% upside based on the Aug. 11 closing price. The consensus rating for the stock remains …

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

Renaissance Technologies LLC significantly increased its stake in Taysha Gene Therapies (NASDAQ: TSHA) by 141.5% in the first quarter, acquiring an additional 242,103 shares. This brings their total holding to 413,203 shares valued at approximately $1.85 million. Despite this institutional confidence and a consensus …

Taysha Gene Therapies Inc (TSHA) Earnings Forecast: Future EPS & Revenue Growth Estimates

EquipmentShare.com (EQPT) Earnings Date and Reports 2026

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was a highly productive period for Taysha," said CEO Sean Nolan, highlighting "the completion of dosing in both the REVEAL pivotal and ASPIRE trials" and progress "toward …

Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast

Taysha Gene Therapies (TSHA) reported a wider second-quarter loss for 2026, missing Wall Street's EPS forecast by $0.01, with shares falling 6.44% in after-hours trading. Despite the earnings miss, the company highlighted significant clinical progress with its lead Rett syndrome gene therapy, TSHA-102, completing …

Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million

Taysha Gene Therapies reported a widening net loss of $46.6 million in Q2 2026, missing EPS estimates, primarily due to increased R&D spending on its lead candidate TSHA-102 for Rett syndrome. Despite the losses, the company strengthened its cash reserves to $455.4 million through …

Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss

Taysha Gene Therapies (TSHA) reported a Q2 loss of $0.13 per share, which is wider than the FactSet estimate of a $0.11 loss. This financial update indicates that the company's performance for the second quarter of 2026 fell short of analyst expectations. The article …

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Taysha Gene Therapies (NASDAQ:TSHA) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite this, the stock rose 5.3% to $6.71, supported by strong liquidity and significant institutional ownership. Analyst sentiment is generally positive, with an average "Buy" rating and …

Taysha Gene Therapies Q2 net loss widens on higher R&D costs

Taysha Gene Therapies reported a widening net loss in the second quarter due to increased research and development costs. The article, sourced from Reuters and provided via TradingView, indicates that the full details are available to subscribers.

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data and FDA feedback on the BLA submission pathway in the first …

Taysha Gene Therapies (TSHA) Is Up 10.2% After Securing Long-Term TSHA-102 Manufacturing Capacity

Taysha Gene Therapies (TSHA) saw a 10.2% stock increase after announcing a commercial supply agreement with Catalent for the manufacturing of TSHA-102, its investigational Rett syndrome gene therapy. This deal secures long-term GMP capacity, preparing Taysha for potential commercialization, though the company remains loss-making …

Taysha Gene faces earnings test as Rett therapy advances

Taysha Gene Therapies Inc. (TSHA) is set to report its second-quarter earnings, with investor focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect a loss of $0.12 per share on $300,000 …

EQPT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Equipmentshare.com Inc. Securities Lawsuit - Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for investors in Equipmentshare.com Inc. (NASDAQ: EQPT) who incurred losses during the class period of January 23, 2026, to June 23, 2026. The lawsuit alleges that the company made false and misleading statements and failed …

EQPT Investors Have Opportunity to Lead EquipmentShare.com Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against EquipmentShare.com Inc. (EQPT) for alleged securities fraud. The lawsuit claims EquipmentShare made false and misleading statements regarding undisclosed related-party transactions during the period of January 23, 2026, to June …

Kaplan Fox Alerts EquipmentShare.Com Inc (NASDAQ: EQPT) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 21, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against EquipmentShare.Com Inc (NASDAQ: EQPT) on behalf of investors who bought common stock during its IPO around January 23, 2026, or between January 23, 2026, and June 23, 2026. The lawsuit alleges that …